Literature DB >> 10795591

Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides.

B Yasin1, M Pang, J S Turner, Y Cho, N N Dinh, A J Waring, R I Lehrer, E A Wagar.   

Abstract

A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide microplate assay was adapted to screen for the ability of 20 host-defense peptides to inactivate herpes simplex virus type 1 and type 2. The procedure required minimal amounts of material, was reproducible, and was confirmed with standard antiviral testing techniques. In screening tests, with the exception of melittin, a highly cytotoxic and hemolytic peptide found in bee venom, the alpha-helical peptides in our test panel (magainins, cecropins, clavanins, and LL-37) caused little viral inactivation. Several beta-sheet peptides (defensins, tachyplesin, and protegrins) inactivated one or both viruses, sometimes with remarkable selectivity. Two peptides were identified as having antiviral activity against both viruses, indolicidin (a tryptophan-rich peptide from bovine neutrophils) and brevinin-1 (a peptide found in frog skin). The antiviral activity of these two peptides was confirmed with standard antiviral assays. Interestingly, the antiviral activity of brevinin-1 was maintained after reduction and carboxamidomethylation, procedures that abolished its otherwise prominent hemolytic and cytotoxic effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10795591     DOI: 10.1007/s100960050457

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  53 in total

Review 1.  Applications of biological pores in nanomedicine, sensing, and nanoelectronics.

Authors:  Sheereen Majd; Erik C Yusko; Yazan N Billeh; Michael X Macrae; Jerry Yang; Michael Mayer
Journal:  Curr Opin Biotechnol       Date:  2010-06-18       Impact factor: 9.740

Review 2.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

3.  Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.

Authors:  Guangshun Wang; Karen M Watson; Robert W Buckheit
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 4.  Development of topical microbicides to prevent the sexual transmission of HIV.

Authors:  Robert W Buckheit; Karen M Watson; Kathleen M Morrow; Anthony S Ham
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

Review 5.  Structural diversity and species distribution of host-defense peptides in frog skin secretions.

Authors:  J Michael Conlon
Journal:  Cell Mol Life Sci       Date:  2011-05-11       Impact factor: 9.261

6.  Implications of the innate immune response to adenovirus and adenoviral vectors.

Authors:  Seth M Gregory; Shoab A Nazir; Jordan P Metcalf
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

7.  Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry.

Authors:  Bushra Yasin; Wei Wang; Mabel Pang; Natalia Cheshenko; Teresa Hong; Alan J Waring; Betsy C Herold; Elizabeth A Wagar; Robert I Lehrer
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells.

Authors:  Aisling S Dugan; Melissa S Maginnis; Joslynn A Jordan; Megan L Gasparovic; Kate Manley; Rebecca Page; Geoffrey Williams; Edith Porter; Bethany A O'Hara; Walter J Atwood
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

9.  A lipid-peptide microbicide inactivates herpes simplex virus.

Authors:  Charles E Isaacs; Jun Hua Jia; Weimin Xu
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Therapeutic Potential of Plants as Anti-microbials for Drug Discovery.

Authors:  Ramar Perumal Samy; Ponnampalam Gopalakrishnakone
Journal:  Evid Based Complement Alternat Med       Date:  2008-06-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.